本页面由Tiger Trade Technology Pte. Ltd.提供服务

众巢医学

1.62
-0.0600-3.57%
盘后1.700.0800+4.94%17:03 EST
成交量:2.40万
成交额:3.91万
市值:622.77万
市盈率:-1.07
高:1.75
开:1.61
低:1.60
收:1.68
52周最高:12.24
52周最低:1.45
股本:384.42万
流通股本:233.20万
量比:0.72
换手率:1.03%
股息:- -
股息率:- -
每股收益(TTM):-1.5200
每股收益(LYR):-0.9885
净资产收益率:-5.93%
总资产收益率:-2.90%
市净率:0.31
市盈率(LYR):-1.64

数据加载中...

2026/01/15

[修订]年度报告

Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
2025/08/22

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2025/07/09

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2025/06/21

SEC问询函

Form CORRESP - Correspondence
2025/06/07

SEC问询函

Form CORRESP - Correspondence
2025/05/20

SEC问询函

Form CORRESP - Correspondence
2025/05/07

SEC问询函

Form CORRESP - Correspondence
2025/04/25

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2025/02/27

SEC问询函

Form CORRESP - Correspondence
2024/04/30

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/05/12

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/05/09

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/05/21

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2021/04/30

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2020/05/08

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2020/04/01

非美公司披露报告

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/23

非美公司披露报告

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/02

非美公司披露报告

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/02/26

超过5%披露

General statement of acquisition of beneficial ownership
2020/02/26

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]